EpiGentek Launches First-to-Market Kits to Detect SARS-CoV-2-Targeted Furin Activity and Screen for Inhibitors Against COVID-19
By HospiMedica International staff writers Posted on 10 Jul 2020 |
Image: EpiGentek Launches First-to-Market Kits to Detect SARS-CoV-2-Targeted Furin Activity and Screen for Inhibitors against COVID-19 (Photo courtesy of EpiGentek)
EpiGentek (Farmingdale, NY, USA) has released a series of SARS-CoV-2 research assays that focuses on studies of SARS-CoV-2 targeted furin or proprotein convertase (PC) cleavage activity.
These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the effective development of drug candidates or therapeutic treatments.
The SARS-CoV-2 spike glycoprotein harbors a furin/PC cleavage site at the boundary between the S1/S2 subunits, which could be cleaved by furin and/or furin-like PCs secreted from host cells and bacteria in the airway epithelium. Unlike the first SARS-CoV, cell entry of SARS-CoV-2 is pre-activated by furin and/or furin-like PCs, reducing its dependence on target cell proteases for entry. The cleavage activation of S-protein is well demonstrated to be essential for SARS-CoV-2 spike-mediated viral binding to ACE2, cell-to-cell fusion, and viral entry into human lung cells.
The first of the two kits by EpiGentek, CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Inhibitor Screening Fast Kit, screens for inhibitors of SARS-CoV-2 targeted furin and PCs. It is an ELISA-like procedure which can be completed within two hours. By using a SARS-CoV-2 specific substrate which is proven to be the same as the complete trimeric form of full length SARS-CoV-2 spike protein in our tests with this kit, the SARS-coV-2 furin site was found to be cleaved not only by furin but also by other serine proteases such as plasmin and human airway trypsin (HAT).
The second kit, CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Activity/Inhibition Assay Kit, quantitatively measures the activity or inhibition levels of furin or furin-like PC as well as facilitated proteases in biological samples such as nasal swabs. It is also similarly ELISA-based and needs only 50 minutes from start to finish. The CoviDrop kits are unique in the market and may be a key tool in better understanding of infection mechanisms and discovery of potent inhibitors against SARS-CoV-2. EpiGentek has also recently released a series of other assay kits to rapidly detect SARS-CoV-2 neutralizing antibodies and measure spike-ACE2 binding activity or inhibition.
"These highly demanded products enable academic and biotechnology to have a much-needed novel approach towards rapidly identifying prevention and therapy initiatives of SARS-CoV-2," said William Lee, EpiGentek's Chief Operating Officer.
Related Links:
EpiGentek
These first-of-its-kind tools can be used to rapidly detect SARS-CoV-2 targeted PC and facilitated proteases using biological samples as well as screen for inhibitors of these enzymes that cleave SARS-CoV-2 proteins. Subsequent implications can be the effective development of drug candidates or therapeutic treatments.
The SARS-CoV-2 spike glycoprotein harbors a furin/PC cleavage site at the boundary between the S1/S2 subunits, which could be cleaved by furin and/or furin-like PCs secreted from host cells and bacteria in the airway epithelium. Unlike the first SARS-CoV, cell entry of SARS-CoV-2 is pre-activated by furin and/or furin-like PCs, reducing its dependence on target cell proteases for entry. The cleavage activation of S-protein is well demonstrated to be essential for SARS-CoV-2 spike-mediated viral binding to ACE2, cell-to-cell fusion, and viral entry into human lung cells.
The first of the two kits by EpiGentek, CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Inhibitor Screening Fast Kit, screens for inhibitors of SARS-CoV-2 targeted furin and PCs. It is an ELISA-like procedure which can be completed within two hours. By using a SARS-CoV-2 specific substrate which is proven to be the same as the complete trimeric form of full length SARS-CoV-2 spike protein in our tests with this kit, the SARS-coV-2 furin site was found to be cleaved not only by furin but also by other serine proteases such as plasmin and human airway trypsin (HAT).
The second kit, CoviDrop SARS-CoV-2 Targeted Proprotein Convertase Activity/Inhibition Assay Kit, quantitatively measures the activity or inhibition levels of furin or furin-like PC as well as facilitated proteases in biological samples such as nasal swabs. It is also similarly ELISA-based and needs only 50 minutes from start to finish. The CoviDrop kits are unique in the market and may be a key tool in better understanding of infection mechanisms and discovery of potent inhibitors against SARS-CoV-2. EpiGentek has also recently released a series of other assay kits to rapidly detect SARS-CoV-2 neutralizing antibodies and measure spike-ACE2 binding activity or inhibition.
"These highly demanded products enable academic and biotechnology to have a much-needed novel approach towards rapidly identifying prevention and therapy initiatives of SARS-CoV-2," said William Lee, EpiGentek's Chief Operating Officer.
Related Links:
EpiGentek
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans